Ddavp is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 30, 2023. Details of Ddavp's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7022340 | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
Apr, 2023
(1 year, 6 months ago) |
Expired
|
| US5674850 | High purity desmopressin produced in large single batches |
Dec, 2013
(10 years ago) |
Expired
|
| US5763407 | High-purity desmopressin produced in large single batches |
Jun, 2013
(11 years ago) |
Expired
|
| US5500413 | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
Jun, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ddavp's patents.
Latest Legal Activities on Ddavp's Patents
Given below is the list of recent legal activities going on the following patents of Ddavp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 30 Apr, 2018 | US7022340 (Litigated) |
| Maintenance Fee Reminder Mailed Critical | 13 Nov, 2017 | US7022340 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 30 May, 2014 | US7022340 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 04 Apr, 2006 | US7022340 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 04 Apr, 2006 | US7022340 (Litigated) |
| Issue Notification Mailed Critical | 15 Mar, 2006 | US7022340 (Litigated) |
| Dispatch to FDC | 03 Mar, 2006 | US7022340 (Litigated) |
| Printer Rush- No mailing | 02 Feb, 2006 | US7022340 (Litigated) |
| Mail Miscellaneous Communication to Applicant | 02 Feb, 2006 | US7022340 (Litigated) |
| Miscellaneous Communication to Applicant - No Action Count | 31 Jan, 2006 | US7022340 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Ddavp is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ddavp's family patents as well as insights into ongoing legal events on those patents.
Ddavp's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ddavp's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 30, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ddavp Generic API suppliers:
Desmopressin Acetate is the generic name for the brand Ddavp. 24 different companies have already filed for the generic of Ddavp, with Abhai Llc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ddavp's generic
How can I launch a generic of Ddavp before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Ddavp's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Ddavp's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Ddavp -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 4 mcg/mL, 1 mL and 10 mL vials | |||||
| 0.0001 | |||||
| 0.1 mg and 0.2 mg |
Alternative Brands for Ddavp
There are several other brand drugs using the same active ingredient (Desmopressin Acetate) as Ddavp. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Acerus Pharms |
| ||
| Ferring |
| ||
| Ferring Pharms Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Desmopressin Acetate, Ddavp's active ingredient. Check the complete list of approved generic manufacturers for Ddavp
About Ddavp
Ddavp is a drug owned by Ferring Pharmaceuticals Inc. Ddavp uses Desmopressin Acetate as an active ingredient. Ddavp was launched by Ferring Pharms Inc in 1995.
Approval Date:
Ddavp was approved by FDA for market use on 06 September, 1995.
Active Ingredient:
Ddavp uses Desmopressin Acetate as the active ingredient. Check out other Drugs and Companies using Desmopressin Acetate ingredient
Dosage:
Ddavp is available in the following dosage forms - solution form for nasal use, tablet form for oral use, spray, metered form for nasal use, injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1MG | TABLET | Prescription | ORAL |
| 0.2MG | TABLET | Prescription | ORAL |
| 0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SPRAY, METERED | Discontinued | NASAL |
| 0.01% | SOLUTION | Discontinued | NASAL |
| 0.015MG/ML | INJECTABLE | Discontinued | INJECTION |
| 0.004MG/ML | INJECTABLE | Prescription | INJECTION |